This content is machine translated CRC, AML and melanoma in focus Molecular mechanisms of tumor plasticity Tumor plasticity, epigenetic reprogramming and the dynamic tumor microenvironment shape the biology of CRC, AML and melanoma and influence their therapeutic vulnerability. Modern therapeutic approaches combine molecular profiles, TME signatures...… CME-Test
View Post 3 min This content is machine translated Hematology and oncology The one-size-fits-all approach is history, personalized medicine is the future The pursuit of individuality was the focus of this year’s Congress of Oncology and Hematology in Switzerland. This paradigm shift is set to change patients’ lives and redefine cancer treatment.…
View Post 8 min This content is machine translated Hematology From anemia to blood cancer – the latest findings at a glance Hematology covers a broad spectrum of indications with very heterogeneous disease patterns. Accordingly, intensive research is being carried out to provide patients with effective treatment. Rarer diseases are examined just…
View Post 8 min This content is machine translated Hematology Leukemia, malignancy and co. on the test bench The annual meeting of the American Society of Hematology (ASH) is considered the most important congress on hematologic diseases worldwide. International experts again exchanged information on current research results and…
View Post 3 min This content is machine translated Myeloid diseases New trends in the treatment of acute myeloid leukemia Understanding about myeloid diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), is becoming more concrete thanks to intensive research. Recent study results have shown that there is…
View Post 2 min This content is machine translated Excellent science Best Abstracts: the most important research results at a glance There is hardly any other discipline in which such great and rapid progress has been made as in oncology and hematology. As the studies honored as Best Abstracts demonstrate, immune…
View Post 2 min This content is machine translated BCL-2 Inhibition The next chapter in blood cancer therapy is opened BCL-2 inhibition represents a milestone in the history of blood cancer treatment. Approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), oral small molecule is now also…
View Post 10 min This content is machine translated Developments in the field of acute leukemias The beginning of a new era in therapy Therapy for AML and ALL is on the move. In the future, it will be much more differentiated. Some new options have already been approved, while others are in development…
View Post 4 min This content is machine translated DKK in Berlin - Leukemia treatment Revolution through personalized therapy Knowledge of molecular markers in leukemias could help identify high-risk patients in the future. In addition, there is an opportunity to develop further targeted therapeutic approaches. Some already approved therapeutics…
View Post 5 min This content is machine translated EHA Congress in Copenhagen New therapeutic options and improved survival in acute leukemias This year, the congress of the European Hematology Association (EHA) was held in Copenhagen from June 9-12. We report encouraging study results on the therapy of AML in elderly patients…
View Post 4 min This content is machine translated Acute myeloid leukemia Treatment options for non-intensively treatable patients. At the EHA Congress in Milan, experts discussed treatment options for patients with acute myeloid leukemia. Elderly patients in particular continue to have a poor prognosis under intensive chemotherapy. Allogeneic…
